Targeting a specific immune pathway to improve treatment for colorectal cancer

Targeting the IL-33/ST2 Pathway in Colorectal Cancer Immunotherapy

NIH-funded research University of Miami School of Medicine · NIH-11017737

This study is looking at a specific immune pathway to see if it can make cancer treatments work better for people with colorectal cancer, and it may involve patients trying out new therapies that could improve their results.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Miami School of Medicine NIH-funded
Lab location1 site (Coral Gables, United States)
Project IDNIH-11017737 on NIH RePORTER

What this research studies

This research investigates the IL-33/ST2 immune pathway to enhance the effectiveness of immunotherapy in colorectal cancer patients. The approach involves understanding how this pathway interacts with existing treatments, particularly those targeting programmed cell death proteins. By utilizing advanced techniques in tumor immunology and bioinformatics, the research aims to identify new therapeutic strategies that could lead to better patient outcomes. Patients may be involved in trials that assess the safety and efficacy of these novel treatments.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with colorectal cancer who have not responded adequately to current immunotherapy treatments.

Not a fit: Patients with early-stage colorectal cancer or those who have not yet undergone immunotherapy may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective immunotherapy options for colorectal cancer patients, potentially improving survival rates.

How similar studies have performed: Previous research has shown promising results in targeting immune pathways for cancer treatment, indicating potential for success in this novel approach.

Where this research is happening

Coral Gables, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapy
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.